Nitric oxide has been proposed as an alternative activator of the HER family and may play a role in this aberrant activation as high iNOS expression has been associated with outcomes in the ER-negative and triple-negative breast cancer setting. Here, NOS2 is linked to triple-negative breast carcinoma.